// Auto-generated - do not edit
export const substanceName = "4-HO-MPMI";
export const sources = [{"id":"protestkit","fileName":"PROTESTKIT - 4-HO-MPMI.json","displayName":"Protest Kit","size":2065},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - 4-HO-MPMI.md","displayName":"TripSit Factsheets","size":1093},{"id":"wikipedia","fileName":"WIKIPEDIA - 4-HO-MPMI.md","displayName":"Wikipedia","size":820}];
export const contents: Record<string, string> = {
  "protestkit": `{
  "url": "https://drugs.tripsit.me/4-ho-mpmi",
  "experiencesUrl": "https://www.reddit.com/search/?q=4-HO-MPMI",
  "name": "4-HO-MPMI",
  "aliases": [
    "lucigenol"
  ],
  "aliasesStr": "lucigenol",
  "summary": "A rare tryptamine derivative first synthesised by David Nichols. This drug, also known as lucigenol, has rarely been documented outside the lab. It is known to be a psychedelic similar to other psychoactive tryptamines, with a potency similar to DOI, but little else is known.",
  "reagents": null,
  "classes": {
    "chemical": [],
    "psychoactive": []
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "500-750ug."
        },
        {
          "name": "Light",
          "value": "750ug-1mg"
        },
        {
          "name": "Common",
          "value": "1-2mg."
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.25 - 1.0 hours"
        },
        {
          "name": "Duration",
          "value": "6.0 - 8.0 hours"
        }
      ]
    }
  ],
  "interactions": null,
  "effects": "Euphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.",
  "categorized_effects": {
    "Physical effects": [
      "decreased appetite",
      "pupil dilation",
      "sweating/chills",
      "muscle tension",
      "insomnia."
    ],
    "Mental effects": [
      "Euphoria",
      "empathy",
      "insight",
      "restlessness",
      "ego softening",
      "confusion"
    ],
    "Sensory effects": [
      "brightened colour",
      "Closed/Open eye visuals",
      "enhanced tactile sensation",
      "change in perception"
    ],
    "Uncategorized effects": [
      "mental/physical stimulation"
    ]
  }
}`,
  "tripsit-factsheets": `# 4-HO-MPMI
*Source: TripSit Factsheets (tripsit.me)*

## Summary

A rare tryptamine derivative first synthesised by David Nichols. This drug, also known as lucigenol, has rarely been documented outside the lab. It is known to be a psychedelic similar to other psychoactive tryptamines, with a potency similar to DOI. Little else is known about the drug.

## Classification
- **Categories:** psychedelic, research-chemical, tentative
- **Also known as:** lucigenol

## Dosage

### Oral
- **Common:** 1-2mg.
- **Light:** 750ug-1mg
- **Threshold:** 500-750ug.

*Note:  Note: As of writing this note, this substance has not been reported on dosages past 2mg. Caution should be given when dosing. The drug is near eqipotent to DOI.*

## Duration
- **Onset:** 15-60 minutes
- **Duration:** 6-8 hours

## Effects
- Euphoria
- empathy
- insight
- brightened colour
- Closed/Open eye visuals
- enhanced tactile sensation
- mental/physical stimulation
- decreased appetite
- pupil dilation
- restlessness
- change in perception
- ego softening
- sweating/chills
- muscle tension
- confusion
- insomnia
`,
  "wikipedia": `# 4-HO-MPMI
*Source: https://en.wikipedia.org/wiki/4-HO-MPMI*

4-HO-MPMI, also known as 4-hydroxy-N-methyl-(Î±,N-trimethylene)tryptamine or as lucigenol, is a psychedelic drug of the pyrrolidinylmethylindole and cyclized tryptamine families.

## Interactions

## Pharmacology

### Pharmacodynamics

The affinity (Ki) of 4-HO-MPMI for the serotonin 5-HT2A receptor has been found to be 13 nM. It produces psychedelic-appropriate responding in animal tests with similar potency as DOI. The drug has two enantiomers, with only the (R)-enantiomer being active.

## Chemistry

### Analogues

Analogues of 4-HO-MPMI include MPMI, 5-MeO-MPMI, 5F-MPMI, CP-135,807, 4-HO-McPeT, 4-HO-pyr-T, and SN-22, among others.

## History

4-HO-MPMI was developed by the team led by David E. Nichols from Purdue University in the late 1990s.
`,
};
